472 related articles for article (PubMed ID: 25904751)
1. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.
Rosenthal EL; Warram JM; de Boer E; Chung TK; Korb ML; Brandwein-Gensler M; Strong TV; Schmalbach CE; Morlandt AB; Agarwal G; Hartman YE; Carroll WR; Richman JS; Clemons LK; Nabell LM; Zinn KR
Clin Cancer Res; 2015 Aug; 21(16):3658-66. PubMed ID: 25904751
[TBL] [Abstract][Full Text] [Related]
2. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
[TBL] [Abstract][Full Text] [Related]
3. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
[No Abstract] [Full Text] [Related]
4. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
[TBL] [Abstract][Full Text] [Related]
5. The Sentinel Margin: Intraoperative
van Keulen S; Nishio N; Birkeland A; Fakurnejad S; Martin B; Forouzanfar T; Cunanan K; Colevas AD; S van den Berg N; Rosenthal E
Clin Cancer Res; 2019 Aug; 25(15):4656-4662. PubMed ID: 31142505
[TBL] [Abstract][Full Text] [Related]
6. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
[TBL] [Abstract][Full Text] [Related]
7. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
8. Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.
van Keulen S; van den Berg NS; Nishio N; Birkeland A; Zhou Q; Lu G; Wang HW; Middendorf L; Forouzanfar T; Martin BA; Colevas AD; Rosenthal EL
Oral Oncol; 2019 Jan; 88():58-65. PubMed ID: 30616798
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
[TBL] [Abstract][Full Text] [Related]
10. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
11. Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.
Moore LS; Rosenthal EL; de Boer E; Prince AC; Patel N; Richman JM; Morlandt AB; Carroll WR; Zinn KR; Warram JM
Mol Imaging Biol; 2017 Aug; 19(4):610-616. PubMed ID: 27830425
[TBL] [Abstract][Full Text] [Related]
12. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
13. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
Schmitz S; Hamoir M; Reychler H; Magremanne M; Weynand B; Lhommel R; Hanin FX; Duprez T; Michoux N; Rommel D; Lonneux M; Cappoen N; Gillain A; Machiels JP
Ann Oncol; 2013 Sep; 24(9):2261-6. PubMed ID: 23704200
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.
Sorace AG; Korb M; Warram JM; Umphrey H; Zinn KR; Rosenthal E; Hoyt K
Ultrasound Med Biol; 2014 Apr; 40(4):755-64. PubMed ID: 24412168
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of optical imaging agents in a fluorescence-guided surgical model of head and neck cancer.
Prince AC; Moore LS; Tipirneni KE; Ramesh T; Limdi MA; Bevans SL; Walsh EM; Greene B; Rosenthal EL; Warram JM
Surg Oncol; 2018 Jun; 27(2):225-230. PubMed ID: 29937175
[TBL] [Abstract][Full Text] [Related]
16. Dynamic optical contrast imaging as a novel modality for rapidly distinguishing head and neck squamous cell carcinoma from surrounding normal tissue.
Tajudeen BA; Taylor ZD; Garritano J; Cheng H; Pearigen A; Sherman AJ; Palma-Diaz F; Mishra P; Bhargava S; Pesce J; Kim I; Sebastian C; Razfar A; Papour A; Stafsudd O; Grundfest W; St John M
Cancer; 2017 Mar; 123(5):879-886. PubMed ID: 27763689
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
Rosenthal EL; Moore LS; Tipirneni K; de Boer E; Stevens TM; Hartman YE; Carroll WR; Zinn KR; Warram JM
Clin Cancer Res; 2017 Aug; 23(16):4744-4752. PubMed ID: 28446503
[No Abstract] [Full Text] [Related]
19. Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients.
Moore LS; Rosenthal EL; Chung TK; de Boer E; Patel N; Prince AC; Korb ML; Walsh EM; Young ES; Stevens TM; Withrow KP; Morlandt AB; Richman JS; Carroll WR; Zinn KR; Warram JM
J Nucl Med; 2017 Feb; 58(2):246-251. PubMed ID: 27587708
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.
de Boer E; Warram JM; Tucker MD; Hartman YE; Moore LS; de Jong JS; Chung TK; Korb ML; Zinn KR; van Dam GM; Rosenthal EL; Brandwein-Gensler MS
Sci Rep; 2015 Jun; 5():10169. PubMed ID: 26120042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
